Butaclamol hydrochloride in newly admitted schizophrenics
- PMID: 778939
Butaclamol hydrochloride in newly admitted schizophrenics
Abstract
Butaclamol hydrochloride, a new type of antipsychotic drug, was evaluated by an uncontrolled study of 13 newly admitted schizophrenic patients. The drug had antipsychotic effects as well as a strong propensity for evoking extrapyramidal side effects. With the maximal daily doses of 30 mg used in this study, therapeutic results obtained were probably somewhat less than optimal.